Highlights

  • NeuroScientific Biopharmaceuticals (ASX:NSB) shares rose nearly 8% to A$0.07 on 13 July 2026, a market capitalisation of about A$25.3 million.
  • In 2025 NSB acquired Isopogen WA, which holds the patented StemSmart mesenchymal stem-cell technology, materially broadening its strategy beyond its original neuroscience peptide research.
  • Its immediate focus is StemSmart therapy for inflammatory immune disorders, including a TGA Special Access program in fistulising Crohn's disease and a planned Phase 2 trial targeted for the second half of 2026.
  • No single price-sensitive ASX announcement was identified for 13 July 2026; the move came amid ongoing interest in the StemSmart program.
  • As a clinical-stage, pre-revenue biotech, NSB faces clinical, regulatory and funding risk, so cash runway, capital raising and dilution remain material investment considerations.

NeuroScientific Biopharmaceuticals Limited (ASX:NSB) was among the small-cap ASX biotech shares that advanced on 13 July 2026, at the time of writing the stock jumped nearly 8% to A$0.07, according to the market snapshot dated that day. At that price the Australian biotechnology company carried a market capitalisation of roughly A$25.3 million (prices delayed at least 20 minutes and may since have changed).

The move comes as NeuroScientific has repositioned itself around a stem-cell therapy platform. While the company's roots are in neuroscience-focused drug research, its 2025 acquisition of the StemSmart technology has moved cell therapy for inflammatory conditions to the centre of its near-term strategy.

What happened to NeuroScientific shares?

On the 13 July 2026 snapshot, NeuroScientific traded at A$0.07, up nearly 8% on the session. At seven cents the stock sits in the micro-cap tier of the ASX health-care sector, where a rise of nearly 8% represents a movement of a fraction of a cent. Such micro-caps can be volatile and thinly traded.

Was there a verified catalyst?

Based on the public information reviewed, no single price-sensitive ASX announcement was identified as published on 13 July 2026 that would directly explain the rise, so the move is more accurately described as unexplained on the public record. NeuroScientific has, however, generated steady news flow around its StemSmart program through 2026, including clinical responses in Crohn's disease under a Special Access framework, manufacturing technology transfer, and preparation for a planned Phase 2 trial. None appears dated 13 July 2026, so the prudent interpretation is that momentum and sentiment around the cell-therapy pivot, rather than a same-day disclosure, drove the move.

What does NeuroScientific Biopharmaceuticals (ASX:NSB) do?

NeuroScientific Biopharmaceuticals is an Australian clinical-stage biotechnology company. It began developing novel peptide-based therapeutics for neurodegenerative conditions, work associated with its EmtinB peptide, but its strategy has broadened substantially into cell therapy following its 2025 acquisition of Isopogen WA Ltd, which holds or has the right to exploit the patented StemSmart mesenchymal stem-cell technology, a bone-marrow-derived MSC product manufactured using a patented process. This gave NeuroScientific a clinical-stage cell-therapy asset with existing data and an immediate focus in inflammatory immune disorders, while the peptide neuroscience work represents earlier-stage optionality.

Key products, technologies and clinical programs

NeuroScientific's lead asset is now StemSmart, its patented MSC platform. Mesenchymal stromal cells are being explored across a range of inflammatory conditions because of their potential immunomodulatory properties. NSB has focused StemSmart initially on fistulising Crohn's disease, a hard-to-treat inflammatory bowel condition, and has also reported activity in steroid-refractory graft-versus-host disease (GvHD). It has treated patients under a Therapeutic Goods Administration (TGA) Special Access framework, which allows use of an unapproved therapy in specific patients outside a formal trial, reporting early clinical responses in Crohn's fistulas and encouraging GvHD signals, plus historical Phase 2 data associated with the technology. Special Access use and early response data are not the same as completed controlled trials; they are early signals requiring confirmation. The original EmtinB neuroprotection program remains a longer-term interest but is earlier stage; StemSmart is the primary near-term value driver.

Clinical-development position

NeuroScientific is a clinical-stage company whose most advanced activity is the StemSmart MSC program, treating patients under the TGA Special Access Scheme while preparing for a formal Phase 2 clinical trial in fistulising Crohn's disease targeted to commence in the second half of 2026. It is important to state the position accurately: Special Access treatment and early response observations are less definitive than the randomised controlled trials required to establish efficacy and support approval. A planned Phase 2 trial is a start-up activity, not a completed study, and cell-therapy development carries manufacturing and regulatory complexity in addition to the usual clinical risk. NeuroScientific has not represented StemSmart as approved, so investors should regard the program as promising but early.

Regulatory and commercial pathway

StemSmart's regulatory pathway runs through standard clinical development and approval requirements, principally via Australia's TGA and, for international ambitions, agencies such as the US FDA and Europe's EMA. Its current use under the Special Access framework provides real-world exposure and early data but is distinct from marketing approval, and NeuroScientific has reported progressing a technology-transfer manufacturing program with a specialist manufacturer. Commercially, near-term value depends on demonstrating clinical benefit in Crohn's disease and potentially GvHD — a multi-year pathway contingent on clinical success, manufacturing scale-up and regulatory outcomes, and revenue is not established.

Latest financial position

As a clinical-stage, pre-revenue biotechnology company, NeuroScientific funds its research from capital rather than product sales. It lodges quarterly Appendix 4C cash-flow reports with the ASX, the authoritative source for its cash position and operating cash outflow. A specific, current cash balance could not be independently verified for this article from the public sources reviewed, so readers should consult NeuroScientific's most recent Appendix 4C for exact figures in Australian dollars. Advancing a cell-therapy program is capital-intensive, and companies of NeuroScientific's size typically require periodic capital raisings that could dilute shareholders. Cash runway and funding are therefore central considerations, and investors should monitor NSB's quarterly reports.

Market opportunity

The conditions NeuroScientific is targeting represent meaningful clinical opportunities. Fistulising Crohn's disease is a serious, hard-to-treat manifestation of inflammatory bowel disease, and steroid-refractory GvHD is a life-threatening complication of transplantation with limited effective options. These reflect the scale of the clinical problem rather than assured revenue: capturing value depends on demonstrating efficacy in controlled trials, obtaining approval, manufacturing at scale and competing with other approaches. The opportunity is real, but converting it into commercialisation is the central and unproven challenge.

Recent official announcements

NeuroScientific's news flow has centred on the StemSmart program: completing the Isopogen acquisition in 2025; reporting early clinical responses in fistulising Crohn's disease under TGA Special Access and encouraging GvHD signals into 2026; initiating a technology-transfer manufacturing run; and advancing preparations for a planned Phase 2 Crohn's trial targeted for the second half of 2026. Investors should rely on NeuroScientific's ASX announcements platform under the code NSB for the definitive record of price-sensitive information.

Potential positive considerations

NeuroScientific's acquisition of StemSmart gave it a clinical-stage cell-therapy asset with existing data and a clear near-term focus, transforming it into a company with an active pipeline in inflammatory disease. The reported early responses in Crohn's fistulas and GvHD, while preliminary, target areas of high unmet need where success could be significant, and its use of the TGA Special Access framework allows it to gather real-world experience while building toward controlled trials. If the planned Phase 2 trial proceeds and generates positive data, these could support the investment thesis, though outcomes remain subject to clinical and regulatory processes.

Main risks and uncertainties

The risks are significant. NeuroScientific is pre-revenue and dependent on external funding, so it faces cash-runway pressure and a likely need for further capital that could dilute shareholders. Its lead StemSmart program is early: Special Access use and preliminary response data are not the same as completed controlled trials, and a Phase 2 study is planned rather than complete. Cell-therapy development adds manufacturing and regulatory complexity to ordinary clinical risk, and timelines can slip. As a seven-cent micro-cap the stock is volatile and the gain could reverse, competition in advanced therapies is growing, and the absence of an identified same-day catalyst underscores that sentiment-driven moves in thinly traded stocks can be short-lived.

What investors may watch next

Investors following NeuroScientific Biopharmaceuticals (ASX:NSB) may monitor several developments. The commencement of the planned Phase 2 Crohn's disease trial, targeted for the second half of 2026, would be a significant clinical milestone, as would further Special Access response data. Progress on the StemSmart manufacturing technology transfer is relevant to trial readiness, and quarterly Appendix 4C reports will show cash balances and any capital raisings. These outcomes are subject to clinical and regulatory processes and are not assured.

A balanced view on NeuroScientific Biopharmaceuticals (ASX:NSB)

NeuroScientific Biopharmaceuticals Limited (ASX:NSB) rose nearly 8% to A$0.07 on 13 July 2026, with no single price-sensitive announcement identified for the day, amid ongoing interest in its StemSmart cell-therapy pivot. The 2025 acquisition of the patented StemSmart technology gave the company an active clinical-stage asset targeting high-unmet-need inflammatory conditions, with early response signals in Crohn's disease and GvHD and a Phase 2 trial planned for the second half of 2026. Against that, NSB remains a small, pre-revenue biotech whose lead program is early, whose strategy carries manufacturing and regulatory complexity, and which is likely to need further funding. The move is best viewed as sentiment in a thinly traded micro-cap. This article is general information only and not financial or medical advice.